Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, Israel.
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Med. 2021 Feb 12;2(2):196-208.e4. doi: 10.1016/j.medj.2020.10.002. Epub 2020 Oct 10.
The gold standard for COVID-19 diagnosis is detection of viral RNA through PCR. Due to global limitations in testing capacity, effective prioritization of individuals for testing is essential.
We devised a model estimating the probability of an individual to test positive for COVID-19 based on answers to 9 simple questions that have been associated with SARS-CoV-2 infection. Our model was devised from a subsample of a national symptom survey that was answered over 2 million times in Israel in its first 2 months and a targeted survey distributed to all residents of several cities in Israel. Overall, 43,752 adults were included, from which 498 self-reported as being COVID-19 positive.
Our model was validated on a held-out set of individuals from Israel where it achieved an auROC of 0.737 (CI: 0.712-0.759) and auPR of 0.144 (CI: 0.119-0.177) and demonstrated its applicability outside of Israel in an independently collected symptom survey dataset from the US, UK, and Sweden. Our analyses revealed interactions between several symptoms and age, suggesting variation in the clinical manifestation of the disease in different age groups.
Our tool can be used online and without exposure to suspected patients, thus suggesting worldwide utility in combating COVID-19 by better directing the limited testing resources through prioritization of individuals for testing, thereby increasing the rate at which positive individuals can be identified. Moreover, individuals at high risk for a positive test result can be isolated prior to testing.
E.S. is supported by the Crown Human Genome Center, Larson Charitable Foundation New Scientist Fund, Else Kroener Fresenius Foundation, White Rose International Foundation, Ben B. and Joyce E. Eisenberg Foundation, Nissenbaum Family, Marcos Pinheiro de Andrade and Vanessa Buchheim, Lady Michelle Michels, and Aliza Moussaieff and grants funded by the Minerva foundation with funding from the Federal German Ministry for Education and Research and by the European Research Council and the Israel Science Foundation. H.R. is supported by the Israeli Council for Higher Education (CHE) via the Weizmann Data Science Research Center and by a research grant from Madame Olga Klein - Astrachan.
COVID-19 的金标准诊断方法是通过 PCR 检测病毒 RNA。由于全球检测能力有限,因此对个人进行有效检测优先级排序至关重要。
我们设计了一种模型,该模型基于与 SARS-CoV-2 感染相关的 9 个简单问题的答案,来估计个体检测呈 COVID-19 阳性的概率。我们的模型是由以色列全国性症状调查的一个子样本和针对以色列几个城市的所有居民进行的目标调查中回答的 200 多万人的回答中设计的。共有 43752 名成年人参与,其中 498 人自我报告 COVID-19 阳性。
我们的模型在以色列的一组保留个体中进行了验证,其 auROC 为 0.737(CI:0.712-0.759),auPR 为 0.144(CI:0.119-0.177),并在以色列以外的美国,英国和瑞典的独立收集症状调查数据集中证明了其适用性。我们的分析揭示了几种症状与年龄之间的相互作用,表明不同年龄组疾病的临床表现存在差异。
我们的工具可以在线使用,并且无需接触疑似患者,因此建议通过优先对个人进行测试来更好地利用有限的测试资源,从而提高识别阳性个体的速度,从而在全球范围内用于对抗 COVID-19。此外,可以在测试之前对检测结果呈阳性的高风险个体进行隔离。
E.S. 得到 Crown Human Genome Center、Larson Charitable Foundation New Scientist Fund、Else Kroener Fresenius Foundation、White Rose International Foundation、Ben B. and Joyce E. Eisenberg Foundation、Nissenbaum Family、Marcos Pinheiro de Andrade 和 Vanessa Buchheim、Lady Michelle Michels 和 Aliza Moussaieff 的支持,并得到德国联邦教育和研究部资助的 Minerva 基金会以及欧洲研究理事会和以色列科学基金会的资助。H.R. 得到以色列高等教育委员会(CHE)通过魏茨曼数据科学研究中心的资助以及来自 Olga Klein-Astrachan 夫人的研究资助。